Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

131.67 +0.58 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361,490
Open 132.00
Bid (Size) 127.70 (10)
Ask (Size) 141.00 (1)
Prev. Close 131.09
Today's Range 130.08 - 136.54
52wk Range 120.00 - 426.56
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
From BeiGene, Ltd.
Via Business Wire
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga

Performance

YTD
-51.15%
-51.15%
1 Month
-25.59%
-25.59%
3 Month
-35.83%
-35.83%
6 Month
-64.32%
-64.32%
1 Year
-60.64%
-60.64%

More News

Read More
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
Where BeiGene Stands With Analysts
Via Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Via Benzinga
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer
Via Benzinga
99 Biggest Movers From Yesterday
Via Benzinga
52 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Via Investor's Business Daily
34 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Via Talk Markets
Recap: BeiGene Q1 Earnings
Via Benzinga
BeiGene Reports First Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
From BeiGene
Via Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
Via InvestorPlace
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
From BeiGene
Via Business Wire
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
BeiGene Introduces Global Environmental, Social, and Governance Strategy
From BeiGene, Ltd.
Via Business Wire
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
From BeiGene
Via Business Wire
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
Via Benzinga
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
From BeiGene
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.